Claire Saffery

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

Rachel Wong, David Cunningham, Yolanda Barbáchano et al. · Annals of Oncology · 2011 · 208 citations · Full text

Medicine, Oncology, Perioperative Medicine +17

MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer

Shelize Khakoo, Paul Carter, Gina Brown et al. · Clinical Cancer Research · 2019 · 136 citations

Medicine, Oncology, Radiology +17

Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial

Alicia Okines, S. Ashley, David Cunningham et al. · Journal of Clinical Oncology · 2010 · 129 citations

Medicine, Oncology, Pharmacology +17

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Reyes Gonzalez-Exposito, Maria Semiannikova, B Griffiths et al. · Journal for ImmunoTherapy of Cancer · 2019 · 115 citations · Full text

Life Sciences, Immunology, Oncology +17